Analyze all protein-coding genes in DNA+RNA—all in a single test.
The OncoExTra test uses whole-exome, whole-transcriptome sequencing across ~20,000 genes to fill in the blanks left by fixed-panel tests.1
Whole-exome DNA sequencing
allows for comprehensive analysis of all protein-coding genes in a sample
Whole-transcriptome RNA sequencing*
allows for detection of fusion genes and transcript variants, including those that are rare1
Whole-exome, whole-transcriptome sequencing ensures that ALL possible protein-coding genes are sequenced and evaluated for actionable variants.1
Go beyond small, fixed panels to personalize care further
Other traditional profiling methods may leave unknowns in your treatment decisions by looking only at fixed panels vs the full exome. Variations can be missed without whole-exome, whole-transcriptome sequencing—even if the test includes both DNA and RNA fixed panels.
Utilize patient-matched tumor-normal sequencing to further refine therapy selection
Every person has unique genetic variants in DNA, but some of them are benign. Patient-matched tumor-normal sequencing is the process of identifying those normal germline DNA variants in a patient’s blood sample, and then subtracting them from those found in the tumor sample to isolate only cancerous variants.2
- Patient-matched tumor-normal sequencing is considered the gold standard of germline subtraction—and is not offered by all comprehensive genomic profiling tests2
- This tumor-informed germline subtraction is an integrated part of every patient’s OncoExTra test, so you can:
Limit false positives by identifying and ruling out benign variants in a patient’s tumor sample vs normal blood sample1
Identify the actionable somatic variants most likely to respond to therapy1
Reduce the overestimation of tumor mutational burden (TMB) calculations by excluding variants also found in the normal sample1,2
The OncoExTra test has:
- A limit of detection of 1% variant allele frequency at DNA hotspots1
- High accuracy with 98.9% sensitivity and >99.9% specificity1
- Optional add-on single immunohistochemical (IHC) stains and/or preselected tumor-specific panels for even more biomarker detail†
Understand the impact the test has on patients
Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®‡
‡OncoExtra was previously known as GEM ExTra.
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Actionable variants were found across many different types of solid tumors1
98% (164/167)
Colorectal Cancer1
96% (53/55)
Lung Cancer1
96% (25/26)
Bladder Cancer1
93% (80/86)
Breast Cancer1
*Whole-transcriptome with select variants reported in New York State
†IHC testing not currently available in New York State
-
References